Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Dexmedetomidine for Supraclavicular Brachial Plexus Block in Distal Radial Fracture Surgery
NCT06235606Phase 3
Key facts
- Status
- Completed
- Start
- May 2024
- Primary completion
- Nov 2025
- Countries
- 1
- Sponsor
- The University of Hong Kong
- Modality
- Small Molecules
- Conditions
- acute pain
01
Overview
Phase 3, randomised trial in acute pain comparing Liposomal bupivacaine + standard bupivacaine with Dexmedetomidine + standard bupivacaine (2 arms). Primary endpoint: Weighted area under curve (AUC) pain score at rest. Started May 2024; status: completed.
02
Design
2 arms- Study design
- Randomized
Liposomal bupivacaine + standard bupivacaine
10ml of 0.5% plain bupivacaine and 10ml of 1.33% liposomal bupivacaine
Dexmedetomidine + standard bupivacaine
19.5ml of 0.5% plain bupivacaine and 0.5ml (50mcg) of dexmedetomidine
03
Who it enrols
Adults aged 18-90 scheduled for distal radial fracture fixation, excluding those with chronic pain, chronic opioid use, impaired renal/liver function, coagulopathy, or psychiatric illness.
04
Endpoints
Primary
Weighted area under curve (AUC) pain score at rest
Beyond the preview
Go deeper on NCT06235606.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235606.